Top Story

Aflibercept for AMD largely maintains visual gains through 212 weeks

March 28, 2017

Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the study results.

In the four arms of the VIEW 1 trial, 1,217 patients with neovascular age-related macular degeneration were randomized to receive 0.5 mg intravitreal Eylea (aflibercept, Regeneron) injections every 4 weeks, 2 mg of aflibercept every 4 weeks, 2 mg of aflibercept every 8 weeks after three initial monthly doses, or 0.5 mg Lucentis (ranibizumab, Genentech) every 4 weeks. Mean best corrected visual acuity at baseline was 55.6 letters, and at the 96-week conclusion of the VIEW 1 trial, patients gained a mean of 10.2 letters.

In the Journals Plus

Glucose variability tied to length of hospital stay, mortality

March 28, 2017
Increased glucose variability is associated with an increased length of hospitalization and short- and long-term mortality in hospitalized adults with and without…
In the Journals

EpiPen settlement proposal not enough, price contributes to higher out-of-pocket costs

March 28, 2017
The $465 million settlement proposed by Mylan, the manufacturer of the epinephrine autoinjector EpiPen, to resolve its misclassification of EpiPen as a generic drug for…
Meeting NewsVideo

VIDEO: Intralesional therapies may improve personalized care for patients with melanoma

March 28, 2017
NEW YORK — Merrick I. Ross, MD, professor in the department of surgery at The University of Texas MD Anderson Cancer Center, discussed the impact of intralesional…
Meeting News

Calabrese: Checkpoint inhibitors may produce rheumatic side effects

March 28, 2017
NEW YORK — Checkpoint inhibitors — which are effective as cancer therapy — may yield side effects that are rheumatic, according to Leonard H
More News Headlines »
CME

Treating Advanced Dry Age-related Macular Degeneration and Geographic Atrophy: Here and Now

This activity is supported by an educational grant from Allergan, Inc.

Dry eye disease (DED) is a condition of the ocular surface in which multiple factors are responsible for the…
More »
Feature Article

Revision Total Hip Arthroplasty Using the Cement-in-Cement Technique

Orthopedics, March/April 2017, Volume 40 Issue 2
The cement-in-cement technique is useful in the setting of revision total hip arthroplasty (THA), especially to gain…
More »
Featured
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies

Video
Meeting News

VIDEO: Rheumatologists should consider sleep, wellness in treatment of patients

March 27, 2017
More »
Advertisement
Advertisement